Abstract
AbstractAccumulating evidence suggested that transient receptor potential melastatin 2–antisense RNA (TRPM2‐AS) played crucial roles in the progression of human cancers. However, the role of TRPM2‐AS was still unknown in osteosarcoma. The aim of this study was to explore the clinical significance of TRPM2‐AS in osteosarcoma patients, and determine the role of TRPM2‐AS on osteosarcoma cell proliferation and apoptosis. In our results, we identified a novel oncogenic long noncoding RNA TRPM2‐AS, which was overexpressed in osteosarcoma tissues and cells, and correlated with advanced Enneking stage, large tumor size and high histological grade in osteosarcoma cases. Survival analysis indicated that osteosarcoma patients with high TRPM2‐AS expression had an obviously shorter overall survival time than those with low TRPM2‐AS expression. Loss‐of‐function studies suggested that suppression of TRPM2‐AS expression inhibited osteosarcoma cell proliferation and induced cell apoptosis through upregulating cleaved caspase‐3 and cleaved caspase‐9 expression. In conclusion, TRPM2‐AS acts as an oncogenic long noncoding RNA and predicts poor prognosis in osteosarcoma.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call